Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 2Completed 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Thoracic 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 4Ovarian Neoplasms 3Hereditary Sensory and Autonomic Neuropathies 3Lung Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Osteosarcoma 1Neoplasms 1Neoplasm Metastasis 1Metastatic Bladder Urothelial Carcinoma 1Leiomyosarcoma 1Clinical Stage III Gastric Cancer AJCC v8 1Carcinoma, Neuroendocrine 1Brain Neoplasms 1

Interventions

Paclitaxel 96Carboplatin 81Bevacizumab 62Gemcitabine 36liposomal doxorubicin 32pembrolizumab 30Topotecan 26olaparib 23Taxes 23niraparib 17Immunoglobulin G 17Disulfides 17Docetaxel 16Cyclophosphamide 16Cisplatin 14Nivolumab 11rucaparib 10durvalumab 10Doxorubicin 9Albumin-Bound Paclitaxel 8sargramostim 7pazopanib 7fludarabine phosphate 7fludarabine 7avelumab 7Magnetic Resonance Spectroscopy 7Ifosfamide 7epacadostat 6Trabectedin 6Sorafenib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Ovarian Neoplasms × berzosertib × Clear all
NCT02595892 2026-04-13

Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
70 enrolled 23 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02627443 2026-04-13

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
35 enrolled 13 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02487095 2025-04-13

Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
62 enrolled 29 charts
EndocrineGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡